|| Checking for direct PDF access through Ovid
Rosiglitazone is a member of a relatively novel class of oral antidiabetic agents, the thiazolidinediones. Clinical trials have shown that the drug improves glycaemic control, as shown by decreased levels of plasma glucose and glycosylated haemoglobin, in patients with type 2 (non-insulin-dependent) diabetes mellitus. Rosiglitazone is effective alone, or in combination with sulphonylureas, metformin or insulin.In contrast with troglitazone, rosiglitazone does not induce cytochrome P450 3A4 and therefore has a low potential for interacting with other drugs.There is no evidence to date that rosiglitazone shares the hepatotoxic potential of troglitazone. However, patients who have experienced liver toxicity during treatment with troglitazone should be discouraged from taking rosiglitazone.